Selective reduction of alpha 2-adrenergic responsiveness in hamster adipose tissue during prolonged starvation.
The influence of fasting on the dual adrenergic control of adipose tissue lipolysis was investigated in hamsters because in this species the adipocytes exhibit both beta-stimulatory and alpha 2-inhibitory adrenergic responses. In adipocytes from fed animals, the number of alpha 2-receptors (identified with [3H]clonidine and [3H]RX 821002) was greater than that of beta-receptors. As in humans, the alpha 2-adrenoceptor number was greater in adipocyte membranes from subcutaneous (inguinal and popliteal) than from internal (perirenal and epididymal) adipose tissues. Despite this difference in alpha 2-adrenoceptor number, the antilipolytic responses to the alpha 2-agonists clonidine and UK 14304 were similar in the two tissues. Food deprivation for a period of 1-6 days induced a net depletion of both adipose tissues. In 6-day starved animals the number of adipocyte alpha 2-adrenoceptors and the maximal antilipolytic effect of UK 14304 were less than 50% of those in fed controls. In contrast, the antilipolytic responses to phenylisopropyladenosine or prostaglandin E1 remained unchanged. Starvation induced a decrease in alpha 2-adrenoceptor number and an increase in beta-adrenergic sensitivity that were greater in adipocytes from subcutaneous than from internal fad pads. The data suggest that the adipocyte beta- and alpha 2-adrenoceptors are independently regulated during starvation. In the adipocyte, the alpha 2-antilipolytic responses and the alpha 2-adrenoceptor levels are dependent on the extent of the adipose mass; they are particularly reduced in emaciated hamsters.
Carpéné
C
C
Institut National de la Santé et de la Recherche Médicale, U 317, Toulouse, France.
Galitzky
J
J
Saulnier-Blache
J S
JS
Lafontan
M
M
D000243:Adenosine Deaminase / Q000494:pharmacology; D000273:Adipose Tissue / Q000187:drug effects / Q000378:metabolism*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D000068438:Brimonidine Tartrate; D002478:Cells, Cultured; D003000:Clonidine / Q000494:pharmacology*; D006224:Cricetinae; D005230:Fatty Acids, Nonesterified / Q000097:blood; D008066:Lipolysis / Q000187:drug effects; D008297:Male; D008647:Mesocricetus; D010660:Phenylisopropyladenosine / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D012016:Reference Values; D013217:Starvation
D000318:Adrenergic beta-Agonists; D001798:Blood Proteins; D005230:Fatty Acids, Nonesterified; D011810:Quinoxalines; D011943:Receptors, Adrenergic, beta; D010660:Phenylisopropyladenosine; D000068438:Brimonidine Tartrate; D000243:Adenosine Deaminase; D000527:Alprostadil; D003000:Clonidine